Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

RolE of AST120 in sarCOpenia preVEntion in pRe-dialYsis Chronic Kidney Disease Patients (RECOVERY): Prospective Open-label Randomized Controlled Multicenter Study

Authors not listed

Gumi Cha Medical Center · 2018

Abstract

This study is to assess the effect of 48 weeks administration of Renamezin capsule on prevention of sarcopenia in pre-dialysis patients with chronic kidney disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-25 MST

Cite this

APA
Anonymous. (2018). RolE of AST120 in sarCOpenia preVEntion in pRe-dialYsis Chronic Kidney Disease Patients (RECOVERY): Prospective Open-label Randomized Controlled Multicenter Study. <em>Gumi Cha Medical Center</em>. https://clinicaltrials.gov/study/NCT03788252
Vancouver
Anonymous. RolE of AST120 in sarCOpenia preVEntion in pRe-dialYsis Chronic Kidney Disease Patients (RECOVERY): Prospective Open-label Randomized Controlled Multicenter Study. Gumi Cha Medical Center. 2018.
BibTeX
@misc{anon2018RolEof, title = {RolE of AST120 in sarCOpenia preVEntion in pRe-dialYsis Chronic Kidney Disease Patients (RECOVERY): Prospective Open-label Randomized Controlled Multicenter Study}, author = {Anonymous}, journal = {Gumi Cha Medical Center}, year = {2018}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings